News
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Pentixapharm Holding AG: Resolves on Rights Issue with an Offering Volume of up to Appr. EUR 20.4 Million; Major Shareholder Eckert Wagniskapital Commits to Fully Exercise Its Subscription Rights
Pentixapharm Holding AG resolves on rights issue worth up to EUR 20.4 million; Eckert Wagniskapital to fully exercise subscription rights for new shares, supporting corporate development and PANDA Phase 3 study -
-
-
-
-
COMMUNIQUÉ DE PRESSE
[68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
Pentixapharm Holding AG receives FDA approval for Phase III study on [68Ga]Ga-PentixaFor in Primary Aldosteronism, targeting billion-dollar revenue potential in underserved market -
COMMUNIQUÉ DE PRESSE
Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
Pentixapharm receives FDA clearance for Phase 3 PANDA study of novel cardiovascular diagnostic program targeting resistant hypertension and primary aldosteronism -
